215 related articles for article (PubMed ID: 8330907)
1. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
Alving CR
Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
[TBL] [Abstract][Full Text] [Related]
2. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen.
Richards RL; Rao M; Wassef NM; Glenn GM; Rothwell SW; Alving CR
Infect Immun; 1998 Jun; 66(6):2859-65. PubMed ID: 9596760
[TBL] [Abstract][Full Text] [Related]
3. Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine.
Alving CR; Richards RL
Immunol Lett; 1990 Aug; 25(1-3):275-9. PubMed ID: 2283158
[TBL] [Abstract][Full Text] [Related]
4. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
5. Lipid A and liposomes containing lipid A as antigens and adjuvants.
Alving CR; Rao M
Vaccine; 2008 Jun; 26(24):3036-45. PubMed ID: 18226433
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
7. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.
Alving CR; Rao M; Steers NJ; Matyas GR; Mayorov AV
Expert Rev Vaccines; 2012 Jun; 11(6):733-44. PubMed ID: 22873129
[TBL] [Abstract][Full Text] [Related]
8. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
Chang SP; Nikaido CM; Hashimoto AC; Hashiro CQ; Yokota BT; Hui GS
J Immunol; 1994 Apr; 152(7):3483-90. PubMed ID: 8144929
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.
Richards RL; Swartz GM; Schultz C; Hayre MD; Ward GS; Ballou WR; Chulay JD; Hockmeyer WT; Berman SL; Alving CR
Vaccine; 1989 Dec; 7(6):506-12. PubMed ID: 2692333
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant effects of nonionic block polymer surfactants on liposome-induced humoral immune response.
Zigterman GJ; Snippe H; Jansze M; Willers JM
J Immunol; 1987 Jan; 138(1):220-5. PubMed ID: 3782798
[TBL] [Abstract][Full Text] [Related]
12. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
[TBL] [Abstract][Full Text] [Related]
13. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
14. Modulation of immunoproteasome subunits by liposomal lipid A.
Steers NJ; Alving CR; Rao M
Vaccine; 2008 Jun; 26(23):2849-59. PubMed ID: 18455279
[TBL] [Abstract][Full Text] [Related]
15. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
[TBL] [Abstract][Full Text] [Related]
16. Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.
Geurtsen J; Fransen F; Vandebriel RJ; Gremmer ER; de la Fonteyne-Blankestijn LJ; Kuipers B; Tommassen J; van der Ley P
Vaccine; 2008 Feb; 26(7):899-906. PubMed ID: 18207288
[TBL] [Abstract][Full Text] [Related]
17. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.
Fries LF; Gordon DM; Richards RL; Egan JE; Hollingdale MR; Gross M; Silverman C; Alving CR
Proc Natl Acad Sci U S A; 1992 Jan; 89(1):358-62. PubMed ID: 1729706
[TBL] [Abstract][Full Text] [Related]
18. Liposomes as vehicles for vaccines.
Alving CR; Banerji B; Shiba T; Kotani S; Clements JD; Richards RL
Prog Clin Biol Res; 1980; 47():339-55. PubMed ID: 7208512
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
Teo WH; Nurul AA; Norazmi MN
Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
